Compare Cytokinetics Inc (CYTK) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Consolidated Edison, Inc. — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Consolidated Edison, Inc. trades at $106.11 (market cap $38.70B). The key difference: Consolidated Edison, Inc. is far larger — about 4.6× Cytokinetics Inc's market cap, and Consolidated Edison, Inc. pays a 3.36% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Consolidated Edison, Inc. for 75 Days on average.
| CYTK | ED | |
|---|---|---|
Market Cap | $8.50B | $38.70B |
Volume | 2,395,556 | 2,154,810 |
Sector | Health | Utilities |
52-Week High | $87.26 | $115.46 |
52-Week Low | $54.76 | $95.37 |
Typical Hold Time | 19 Days | 75 Days |
Enterprise Value | $8.60B | $65.55B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
ED (Consolidated Edison) trades at $105.99, up 0.83% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue grew to $16.92B with a net income margin of 12.53%, while recent earnings have been mixed with a Q1 2026 miss. The company maintains a solid dividend, with a recent $0.89 payout announced for September 2026, and is highlighted in news for its economic impact in New York and involvement in electric bus infrastructure.
Outlook is balanced; ED offers stability as a utility stock with consistent dividends and moderate growth, but faces risks from debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings. Key catalysts include the upcoming investor presentation on October 6, 2026, and execution on capital investments. Risks involve regulatory changes and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
